|
Persistent Identifier
|
perma:LIST.RJS2TC |
|
Publication Date
|
2026-07-06 |
|
Title
| AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper [* Cross-Reference *] |
|
Other Identifier
| https://doi.org/10.1111/all.15994
OpenAlex ID: https://openalex.org/W4391173140 |
|
Author
| Michelle C. Turner (Universitat Pompeu Fabra, Barcelona Institute for Global Health, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)Universitat Pompeu Fabra, Barcelona Institute for Global Health, Centro de Investigación Biomédica en Red de Epidemiología y Salud PúblicaORCIDhttps://orcid.org/0000-0002-6431-1997
Urszula Radzikowska (University of Zurich, CK-CARE)University of Zurich, CK-CAREORCIDhttps://orcid.org/0000-0002-7341-9764
Denisa Ferastraoaru (Albert Einstein College of Medicine, Montefiore Medical Center)Albert Einstein College of Medicine, Montefiore Medical CenterORCIDhttps://orcid.org/0000-0002-9799-4800
Mariona Pascal (Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona)Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de BarcelonaORCIDhttps://orcid.org/0000-0003-0549-9720
Pieter Wesseling (Princess Máxima Center, Amsterdam University Medical Centers)Princess Máxima Center, Amsterdam University Medical CentersORCIDhttps://orcid.org/0000-0001-5453-5201
Alexandra McCraw (Guy's Hospital, King's College London, King's College Hospital)Guy's Hospital, King's College London, King's College HospitalORCIDhttps://orcid.org/0009-0008-2412-4389
Claudine Backes (Luxembourg Institute of Health, National Cancer Registry)Luxembourg Institute of Health, National Cancer RegistryORCIDhttps://orcid.org/0000-0003-3300-4959
Heather J. Bax (Guy's Hospital, King's College London, King's College Hospital)Guy's Hospital, King's College London, King's College HospitalORCIDhttps://orcid.org/0000-0003-0432-4160
Christoph BergmannORCIDhttps://orcid.org/0000-0002-2076-8813
Rodolfo Bianchini (University of Veterinary Medicine Vienna, Medical University of Vienna)University of Veterinary Medicine Vienna, Medical University of ViennaORCIDhttps://orcid.org/0000-0003-0351-6937
Luigi Cari (University of Perugia)University of PerugiaORCIDhttps://orcid.org/0000-0003-0698-3872
Leticia de las VecillasORCIDhttps://orcid.org/0000-0003-4969-5678
Elena Izquierdo (Universidad San Pablo CEU)Universidad San Pablo CEUORCIDhttps://orcid.org/0000-0002-3355-2798
Frida Lind‐Holm Mogensen (University of Luxembourg, Luxembourg Institute of Health, Luxembourg Institute of Science and Technology)University of Luxembourg, Luxembourg Institute of Health, Luxembourg Institute of Science and TechnologyORCIDhttps://orcid.org/0000-0002-3497-2321
Alessandro Michelucci (Luxembourg Institute of Health)Luxembourg Institute of HealthORCIDhttps://orcid.org/0000-0003-1230-061X
Petr V. Nazarov (Luxembourg Institute of Health)Luxembourg Institute of HealthORCIDhttps://orcid.org/0000-0003-3443-0298
Simone P. Niclou (University of Luxembourg, Luxembourg Institute of Health, Luxembourg Institute of Science and Technology)University of Luxembourg, Luxembourg Institute of Health, Luxembourg Institute of Science and TechnologyORCIDhttps://orcid.org/0000-0002-3417-9534
Giuseppe Nocentini (University of Perugia)University of PerugiaORCIDhttps://orcid.org/0000-0002-5209-0488
Markus Ollert (Odense University Hospital, Luxembourg Institute of Health)Odense University Hospital, Luxembourg Institute of HealthORCIDhttps://orcid.org/0000-0002-8055-0103
Matthias Preusser (Medical University of Vienna)Medical University of ViennaORCIDhttps://orcid.org/0000-0003-3541-2315
Nataliya Rohr‐Udilova (Austrian Breast & Colorectal Cancer Study Group, Medical University of Vienna)Austrian Breast & Colorectal Cancer Study Group, Medical University of ViennaORCIDhttps://orcid.org/0000-0003-2432-3632
Andrea Scafidi (University of Luxembourg, Luxembourg Institute of Health, Luxembourg Institute of Science and Technology)University of Luxembourg, Luxembourg Institute of Health, Luxembourg Institute of Science and TechnologyORCIDhttps://orcid.org/0000-0002-3089-2439
Réka Tóth (Luxembourg Institute of Health)Luxembourg Institute of HealthORCIDhttps://orcid.org/0000-0002-6096-1052
Mieke Van Hemelrijck (King's College London)King's College LondonORCIDhttps://orcid.org/0000-0002-7317-0858
Michael Weller (University of Zurich, University Hospital of Zurich)University of Zurich, University Hospital of ZurichORCIDhttps://orcid.org/0000-0002-1748-174X
Uta Jappe (Institute for Integrative and Experimental Genomics, Research Center Borstel - Leibniz Lung Center, German Center for Lung Research, University of Lübeck)Institute for Integrative and Experimental Genomics, Research Center Borstel - Leibniz Lung Center, German Center for Lung Research, University of LübeckORCIDhttps://orcid.org/0000-0001-5602-3672
María M. Escribese (Universidad San Pablo CEU)Universidad San Pablo CEUORCIDhttps://orcid.org/0000-0001-5057-5150
Erika Jensen‐Jarolim (University of Veterinary Medicine Vienna, Medical University of Vienna)University of Veterinary Medicine Vienna, Medical University of ViennaORCIDhttps://orcid.org/0000-0003-4019-5765
Sophia N. Karagiannis (Guy's Hospital, King's College London, Breast Cancer Now, King's College Hospital)Guy's Hospital, King's College London, Breast Cancer Now, King's College HospitalORCIDhttps://orcid.org/0000-0002-4100-7810
Aurélie Poli (Luxembourg Institute of Health)Luxembourg Institute of HealthORCIDhttps://orcid.org/0000-0002-7986-0761 |
|
Point of Contact
|
Use email button above to contact.
LIST QDKM (LIST) |
|
Description
| Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune–glioma interactions to ultimately improve patient prognosis and survival. (2024-01-24)
***This entry has been automatically imported via OpenAlex by LIST harvest scripts. Please refer to https://doi.org/10.1111/all.15994 for the original and latest version of the publication*** (2026-07-01) |
|
Subject
| Medicine, Health and Life Sciences |
|
Keyword
| Medicine
Glioma
Allergy
Immunology
Immune system
Immunotherapy
Disease
Internal medicine
Cancer research |
|
Topic Classification
| Allergic Rhinitis and Sensitization
Asthma and respiratory diseases
Mast cells and histamine |
|
Deposit Date
| 2024-01-24 |
|
Data Type
| Article |
|
Data Source
| Allergy |